Drug
Cholic Acid
Cholic Acid is a pharmaceutical drug with 5 clinical trials. Historical success rate of 80.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
80.0%
Based on 4 completed trials
Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
100%(4 trials)
Terminated
1(20%)
Phase Distribution
Ph phase_3
2
40%
Ph phase_1
1
20%
Ph phase_2
1
20%
Ph not_applicable
1
20%
Phase Distribution
1
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
2(40.0%)
N/ANon-phased studies
1(20.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
80.0%
4 of 5 finished
Non-Completion Rate
20.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(4)
Terminated(1)
Detailed Status
Completed4
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
80.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 32 (40.0%)
N/A1 (20.0%)
Trials by Status
terminated120%
completed480%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_2
Cholic Acid for Hepatic Steatosis in Lipodystrophy
NCT00457639
completedphase_1
Smith-Lemli-Opitz Syndrome and Cholic Acid
NCT03720990
completedphase_3
Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis
NCT01115582
completedphase_3
Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis
NCT01438411
terminatednot_applicable
Study of Bile Acids in Patients With Peroxisomal Disorders
NCT00004442
Clinical Trials (5)
Showing 5 of 5 trials
NCT00457639Phase 2
Cholic Acid for Hepatic Steatosis in Lipodystrophy
NCT03720990Phase 1
Smith-Lemli-Opitz Syndrome and Cholic Acid
NCT01115582Phase 3
Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid Synthesis
NCT01438411Phase 3
Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis
NCT00004442Not Applicable
Study of Bile Acids in Patients With Peroxisomal Disorders
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5